Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.

Stubblefield MD, McNeely ML, Alfano CM, Mayer DK.

Cancer. 2012 Apr 15;118(8 Suppl):2250-60. doi: 10.1002/cncr.27463. Review.

2.

A prospective surveillance model for rehabilitation for women with breast cancer.

Stout NL, Binkley JM, Schmitz KH, Andrews K, Hayes SC, Campbell KL, McNeely ML, Soballe PW, Berger AM, Cheville AL, Fabian C, Gerber LH, Harris SR, Johansson K, Pusic AL, Prosnitz RG, Smith RA.

Cancer. 2012 Apr 15;118(8 Suppl):2191-200. doi: 10.1002/cncr.27476. Review.

3.

A prospective model of care for breast cancer rehabilitation: postoperative and postreconstructive issues.

McNeely ML, Binkley JM, Pusic AL, Campbell KL, Gabram S, Soballe PW.

Cancer. 2012 Apr 15;118(8 Suppl):2226-36. doi: 10.1002/cncr.27468. Review.

4.

Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer.

Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, Rowden D.

Cancer. 2012 Apr 15;118(8 Suppl):2207-16. doi: 10.1002/cncr.27469. Review.

5.

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH.

Support Care Cancer. 2012 Dec;20(12):3355-64. doi: 10.1007/s00520-012-1492-x.

PMID:
22584733
6.

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH.

Support Care Cancer. 2009 Dec;17(12):1483-91. doi: 10.1007/s00520-009-0613-7.

PMID:
19330359
7.

Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care.

Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH.

Cancer. 2012 Apr 15;118(8 Suppl):2237-49. doi: 10.1002/cncr.27467. Review.

8.

A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Watanabe T, Bain S, Hausheer FH.

Jpn J Clin Oncol. 2008 Nov;38(11):748-54. doi: 10.1093/jjco/hyn100.

9.

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH.

Support Care Cancer. 2009 Aug;17(8):1071-80. doi: 10.1007/s00520-008-0550-x.

PMID:
19089463
10.
11.

Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.

Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK.

Support Care Cancer. 2012 Oct;20(10):2433-9. doi: 10.1007/s00520-011-1365-8.

PMID:
22231480
12.

Case report of a patient with chemotherapy-induced peripheral neuropathy treated with manual therapy (massage).

Cunningham JE, Kelechi T, Sterba K, Barthelemy N, Falkowski P, Chin SH.

Support Care Cancer. 2011 Sep;19(9):1473-6. doi: 10.1007/s00520-011-1231-8.

PMID:
21766161
13.

Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy.

Yoon J, Jeon JH, Lee YW, Cho CK, Kwon KR, Shin JE, Sagar S, Wong R, Yoo HS.

J Acupunct Meridian Stud. 2012 Aug;5(4):156-65. doi: 10.1016/j.jams.2012.05.003.

14.

Effects of sweet bee venom pharmacopuncture treatment for chemotherapy-induced peripheral neuropathy: a case series.

Park JW, Jeon JH, Yoon J, Jung TY, Kwon KR, Cho CK, Lee YW, Sagar S, Wong R, Yoo HS.

Integr Cancer Ther. 2012 Jun;11(2):166-71. doi: 10.1177/1534735411413265.

PMID:
21715371
15.

Chemotherapy-induced peripheral neurotoxicity.

Cavaletti G, Marmiroli P.

Nat Rev Neurol. 2010 Dec;6(12):657-66. doi: 10.1038/nrneurol.2010.160. Review.

PMID:
21060341
16.

[Chemotherapy-induced peripheral neuropathy: an unresolved issue].

Velasco R, Bruna J.

Neurologia. 2010 Mar;25(2):116-31. Review. Spanish.

17.
18.

Stakeholder perspectives on dissemination and implementation of a prospective surveillance model of rehabilitation for breast cancer treatment.

Stout NL, Andrews K, Binkley JM, Schmitz KH, Smith RA.

Cancer. 2012 Apr 15;118(8 Suppl):2331-4. doi: 10.1002/cncr.27470. Review.

19.

Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer.

Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS.

Clin J Oncol Nurs. 2005 Apr;9(2):189-93. Review.

PMID:
15853162
20.

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group., Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG.

Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004.

PMID:
23668917
Items per page

Supplemental Content

Support Center